Pyrukynd cleared for hemolytic anemia in adults with rare genetic disorder Agios Pharmaceuticals’ Pyrukynd (mitapivat; tablets) has been approved for treating hemolytic anemia in adults with pyruvate ...

Agios Pharmaceuticals AGIO announced that its lead drug, Pyrukynd (mitapivat), an oral pyruvate kinase (PK) activator, has ...

PYRUKYND is the only medicine approved in the EU for adults with transfusion-dependent and non-transfusion-dependent alpha- or ...

Agios Pharmaceuticals AGIO announced that the FDA has approved Aqvesme (mitapivat) for the treatment of adult patients with alpha- or beta-thalassemia. With this approval, Aqvesme becomes the only FDA ...

The FDA approved mitapivat (Aqvesme) as a disease-modifying treatment for anemia in adults with alpha- or beta-thalassemia, a rare inherited blood disease that affects hemoglobin production. An oral ...

The U.S. Food and Drug Administration (FDA) on Tuesday approved Agios Pharmaceuticals, Inc.’s (NASDAQ: AGIO) Aqvesme (mitapivat), an oral pyruvate kinase (PK) activator, for anemia in adults with ...

CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients ...

Agios Pharmaceuticals AGIO announced that it has submitted a supplemental new drug application (sNDA) to the FDA seeking accelerated approval for the label expansion of its lead drug, mitapivat, for ...

Agios Pharmaceuticals AGIO announced that the FDA has not yet given its decision related to the company’s supplemental new drug application (sNDA) seeking approval for its only marketed drug, Pyrukynd ...